| Literature DB >> 27313462 |
Zhilan Chen1, Kecheng Huang2, Zhiyong Lu3, Song Deng4, Jiaqiang Xiong2, Jia Huang2, Xiong Li5, Fangxu Tang2, Zhihao Wang6, Haiying Sun2, Lin Wang2, Shasha Zhou2, Xiaoli Wang2, Yao Jia2, Ting Hu2, Juan Gui7, Dongyi Wan2, Ding Ma2, Shuang Li2, Shixuan Wang2.
Abstract
The purpose of this study was to identify risk factors in patients with surgically treated node-positive IB1-IIB cervical cancer and to establish a risk model for disease-free survival (DFS) and overall survival (OS). A total of 170 patients who underwent radical hysterectomy and bilateral pelvic lymphadenectomy as primary treatment for node-positive International Federation of Gynaecology and Obstetrics (FIGO) stage IB1-IIB cervical cancer from January 2002 to December 2008 were retrospectively analyzed. Five published risk models were evaluated in this population. The variables, including common iliac lymph node metastasis and parametrial invasion, were independent predictors of outcome in a multivariate analysis using a Cox regression model. Three distinct prognostic groups (low, intermediate, and high risk) were defined using these variables. Five-year DFS rates for the low-, intermediate-, and high-risk groups were 73.7%, 60.0%, and 25.0%, respectively (P<0.001), and 5-year OS rates were 81.9%, 42.8%, and 25.0%, respectively (P<0.001). The risk model derived in this study provides a novel means for assessing prognosis of patients with node-positive stage IB1-IIB cervical cancer. Future study will focus on external validation of the model and refinement of the risk scoring systems by adding new biologic markers.Entities:
Keywords: cervical cancer; disease-free survival; lymph node metastasis; overall survival; risk model
Year: 2016 PMID: 27313462 PMCID: PMC4892859 DOI: 10.2147/OTT.S94151
Source DB: PubMed Journal: Onco Targets Ther ISSN: 1178-6930 Impact factor: 4.147
Demographic and clinical characteristics of patients (n=170)
| Characteristics | Patients
| |
|---|---|---|
| N | % | |
| Age at diagnosis (years) | ||
| <30 | 7 | 4.1 |
| 30–39 | 64 | 37.6 |
| 40–49 | 63 | 37.1 |
| 50–59 | 29 | 17.1 |
| 60–69 | 7 | 4.1 |
| Parity | ||
| <2 | 76 | 44.7 |
| ≥2 | 85 | 50.0 |
| Unknown | 9 | 5.3 |
| Histology | ||
| Squamous | 145 | 85.3 |
| Adenocarcinoma | 19 | 11.2 |
| Adenosquamous | 6 | 3.5 |
| Grade | ||
| 1 | 18 | 10.6 |
| 2 | 90 | 52.9 |
| 3 | 62 | 36.5 |
| Tumor size | ||
| <4 cm | 122 | 71.8 |
| ≥4 cm | 48 | 28.2 |
| Number of positive lymph nodes | ||
| 1 | 66 | 38.8 |
| 2 | 42 | 24.7 |
| 3 | 29 | 17.1 |
| 4 | 12 | 7.1 |
| ≥5 | 21 | 12.4 |
| Bilaterality of lymph node metastasis | ||
| Unilateral | 99 | 58.2 |
| Bilateral | 71 | 41.8 |
| Common iliac lymph node metastasis | ||
| No | 145 | 85.3 |
| Yes | 25 | 14.7 |
| FIGO stage | ||
| IB1 | 76 | 44.7 |
| IB2 | 29 | 17.1 |
| IIA | 49 | 28.9 |
| IIB | 16 | 9.4 |
| Lymph-vascular space invasion | ||
| No | 124 | 72.9 |
| Yes | 46 | 27.1 |
| Vaginal margin | ||
| Negative | 161 | 94.7 |
| Positive | 9 | 5.3 |
| Parametrial infiltration | ||
| No | 152 | 89.4 |
| Yes | 18 | 10.6 |
| Corpus invasion | ||
| No | 154 | 90.6 |
| Yes | 16 | 9.4 |
| Deep stromal invasion | ||
| No | 72 | 42.4 |
| Yes | 98 | 57.6 |
Abbreviation: FIGO, International Federation of Gynaecology and Obstetrics.
Factors associated with DFS and OS after multivariate Cox regression after including the risk model as a covariate (n=170)
| Variables | No of patients | DFS
| OS
| ||
|---|---|---|---|---|---|
| HR | HR | ||||
| Our risk model (score) | |||||
| 0 | 131 | 1 | 1 | ||
| 1 | 35 | 3.21 | <0.001 | 3.04 | 0.001 |
| 2 | 4 | 7.38 | 0.001 | 14.52 | <0.001 |
Abbreviations: DFS, disease-free survival; OS, overall survival; HR, hazards ratio.
Prognostic risk models
| Factors | DFS model
|
|---|---|
| Scores | |
| Parametrial involvement | +1 |
| Common iliac lymph node metastasis | +1 |
| Risk groups | Points |
| Low | 0 |
| Medium | 1 |
| High | 2 |
Abbreviation: DFS, disease-free survival.
Figure 1Kaplan-Meier analysis of DFS and OS in the risk groups.
Notes: DFS rates among the risk groups showed statistically significant differences using Log Rank test (A). OS rates among the risk groups showed statistically significant differences using Log Rank test (B). P<0.05 was considered to be significant.
Abbreviations: DFS, disease-free survival; OS, overall survival; LR, low risk; HR, high risk; IR, intermediate risk.
Factors associated with DFS in univariate analysis (n=170)
| Variables | No of patients | DFS
| ||
|---|---|---|---|---|
| Five-year rate (%) | HR | |||
| Age at diagnosis (years) | ||||
| <35 | 34 | 73.4 | 1 | |
| 35–45 | 82 | 65.3 | 1.26 | 0.57 |
| ≥45 | 54 | 57.6 | 2.00 | 0.09 |
| Parity | ||||
| <2 | 76 | 68.9 | 1 | |
| ≥2 | 85 | 62.3 | 1.34 | 0.31 |
| Unknown | 9 | |||
| Histology | ||||
| Squamous | 145 | 64.1 | 1 | |
| Adenocarcinoma and adenosquamous | 25 | 70.4 | 0.95 | 0.89 |
| Grade | ||||
| 1 | 18 | 76.2 | 1 | |
| 2 | 90 | 63.7 | 1.43 | 0.51 |
| 3 | 62 | 64.8 | 1.89 | 0.24 |
| Tumor size | ||||
| <4 cm | 122 | 66.0 | 1 | |
| ≥4 cm | 48 | 62.5 | 1.31 | 0.36 |
| Number of positive lymph nodes | ||||
| <3 | 107 | 73.7 | 1 | |
| ≥3 | 63 | 49.6 | 1.85 | 0.02 |
| Bilaterality of lymph node metastasis | ||||
| Unilateral | 99 | 72.0 | 1 | |
| Bilateral | 71 | 54.4 | 1.47 | 0.16 |
| Common iliac lymph node metastasis | ||||
| No | 145 | 70.3 | 1 | |
| Yes | 25 | 35.6 | 3.19 | <0.001 |
| FIGO stage | ||||
| IB1 | 76 | 74.4 | 1 | |
| IB2 | 29 | 70.3 | 1.29 | 0.55 |
| IIA | 49 | 53.6 | 2.07 | 0.02 |
| IIB | 16 | 57.9 | 1.69 | 0.24 |
| Lymph vascular space invasion | ||||
| No | 124 | 74.4 | 1 | |
| Yes | 46 | 55.1 | 1.71 | 0.055 |
| Vaginal margin | ||||
| Negative | 161 | 72.9 | 1 | |
| Positive | 9 | 27.8 | 1.90 | 0.17 |
| Parametrial infiltration | ||||
| No | 152 | 73.8 | 1 | |
| Yes | 18 | 37.0 | 2.76 | 0.002 |
| Corpus invasion | ||||
| No | 156 | 73.4 | 1 | |
| Yes | 14 | 55.0 | 1.39 | 0.45 |
| Deep stromal invasion | ||||
| No | 72 | 70.3 | 1 | |
| Yes | 98 | 60.4 | 1.61 | 0.10 |
Abbreviations: DFS, disease-free survival; HR, hazards ratio; FIGO, Federation of Gynaecology and Obstetrics.
Factors associated with DFS in multivariate Cox regression before including the risk model as a covariate (n=170)
| Variables | DFS
| |
|---|---|---|
| HR | ||
| Common iliac lymph node metastasis | ||
| No | 1 | |
| Yes | 3.18 | <0.001 |
| Parametrial infiltration | ||
| No | 1 | |
| Yes | 2.74 | 0.002 |
Abbreviations: DFS, disease-free survival; HR, hazards ratio.
Performance of the population in different models for different risk groups
| Risk models | n | Five-year DFS | HR | 95% CI | Five-year OS | HR | 95% CI | ||
|---|---|---|---|---|---|---|---|---|---|
| Alvarez et al | |||||||||
| Low | 8 | 100 | 0 | 0 | 0.98 | ||||
| Low–intermediate | 87 | 71.9 | 1 | 76.9 | 1 | ||||
| High–intermediate | 69 | 52.9 | 1.63 | 0.94–2.81 | 0.08 | 63.1 | 1.68 | 0.10 | |
| High | 6 | 50 | 2.27 | 0.68–7.55 | 0.18 | 53.3 | 2.28 | 0.27 | |
| Lai et al | |||||||||
| Low | 64 | 78.2 | 1 | 82.8 | 1 | ||||
| Intermediate | 62 | 62.4 | 1.70 | 0.85–3.42 | 0.14 | 69.9 | 2.03 | 0.90–4.55 | 0.09 |
| High | 44 | 49.1 | 2.85 | 1.42–5.66 | 0.003 | 58.3 | 3.28 | 1.44–7.43 | 0.005 |
| Samlal et al | |||||||||
| Low | 129 | 66.9 | 1 | 81.5 | 1 | ||||
| High | 41 | 58.5 | 1.54 | 0.88–2.71 | 0.13 | 56.7 | 1.89 | 0.99–3.52 | 0.053 |
| Aoki et al | |||||||||
| Low | 63 | 79.9 | 1 | 77.7 | 1 | ||||
| Intermediate | 92 | 60.2 | 2.03 | 1.05–3.94 | 0.035 | 68.9 | 2.36 | 1.06–5.23 | 0.035 |
| High | 15 | 30 | 4.44 | 1.91–10.31 | <0.001 | 34.6 | 6.10 | 2.35–15.84 | <0.001 |
| Park et al | |||||||||
| Low | 113 | 67.3 | 1 | 78.2 | 1 | ||||
| Intermediate | 57 | 60.1 | 1.58 | 0.93–2.69 | 0.09 | 60.1 | 1.78 | 0.97–3.26 | 0.06 |
| High | 0 | ||||||||
| The present study | |||||||||
| Low | 131 | 73.7 | 1 | 81.9 | 1 | ||||
| Intermediate | 35 | 60.0 | 3.21 | 1.85–5.59 | <0.001 | 42.8 | 3.04 | 1.61–5.73 | 0.001 |
| High | 4 | 25.0 | 7.38 | 2.23–24.50 | 0.001 | 25.0 | 14.52 | 4.15–50.88 | <0.001 |
Abbreviations: DFS, disease-free survival; HR, hazards ratio; OS, overall survival; CI, confidence interval.
Prognostic models for early-stage cervical cancer treated with radical hysterectomy and pelvic lymph node dissection
| References | Characteristics
| Prognostic variables employed in the model
| |||||||
|---|---|---|---|---|---|---|---|---|---|
| n | Stage | Histology | TS | LVSI | PMI | Number of LNM | Histology | Others | |
| Alvarez et al | 185 | IB-IIA | SCC | + | + | ||||
| Lai et al | 105 | IB-IIB | SCC/ASC | + | + | DNA index | |||
| Samlal et al | 68 | IB-IIA | SCC/AC | + | + | ||||
| Aoki et al | 59 | IB-IIB | SCC/AC/ASC | + | + | ||||
| Park et al | 188 | IA2-IIA | SCC/AC/ASC | + | + | + | |||
Abbreviations: SCC, squamous carcinoma; AC, adenocarcinoma; ASC, adenosquamous carcinoma; TS, tumor size; LVSI, lymphatic/vascular space involvement; PMI, parametrial involvement; LNM, lymph node metastasis.